Cambrex Reports First Quarter 2013 Financial Results
- Company reports strong first quarter sales and operating profit growth -
EAST RUTHERFORD, N.J., May 3, 2013 /PRNewswire/ — Cambrex Corporation (NYSE: CBM) reports results for the first quarter ended March 31, 2013.
- First quarter sales increased by 5.7% and excluding the impact of foreign currency, sales increased 4.7% compared to the first quarter of 2012.
- First quarter Adjusted EBITDA increased 7.6% to $16.8 million compared to $15.6 million in the first quarter of 2012.
- Debt, net of cash was $41.1 million at the end of the first quarter, an increase of $0.7 million during the quarter.
- 2013 full year sales and EBITDA guidance confirmed (see Financial Expectations section).
“The first quarter was a solid quarter for us, with overall growth driven by increases in custom development and custom manufacturing, demonstrating the strength of our portfolio of innovator products. We continue to expect strong sales and EBITDA increases for the full year, consistent with our previous guidance,” commented Steven M. Klosk, President and Chief Executive Officer of Cambrex. “We remain on target for implementation of our key growth-based capital projects, including the large investment at our Iowa facility to expand overall capacity and to make commercial launch material pursuant to a supply agreement signed in 2012.”
First Quarter 2013 Operating Results – Continuing Operations
Sales of $74.6 million were 5.7% higher compared to the same period last year, including the favorable impact of foreign exchange of 1.0%. This increase was primarily due to higher custom development sales related to clinical phase projects and higher sales of certain active pharmaceutical ingredients for branded commercial products.
Gross margins increased to 33.2% from 31.8% compared to the same period last year. This increase was due to higher sales and production volumes and slightly higher pricing partially offset by unfavorable product mix. Foreign exchange did not have an impact on gross margins in the first quarter of 2013.
Selling, general and administrative expenses were $11.1 million compared to $10.0 million in the same period last year. The increase was mainly due to increased personnel costs including performance share units’ expense as a result of a higher Cambrex share price and additional shares expected to vest due to recent favorable performance by the Company against its peers.
Research and development (“R&D”) expenses were $2.2 million compared to $2.4 million in the same period last year. The decrease was primarily due to increased absorption of R&D expenses into inventory and cost of goods sold due to higher revenue-generating custom development activity.
Operating profit increased to $16.1 million from $10.1 million in the same period last year. Adjusted operating profit increased to $11.5 million from $10.1 million in the same period last year. The increase in adjusted operating profit was primarily the result of higher gross profit partially offset by higher SG&A expenses. EBITDA was $21.5 million compared to $15.6 million in the same period last year. Adjusted EBITDA was $16.8 million compared to $15.6 million in the same period last year. Adjusted operating profit and adjusted EBITDA exclude a gain on sale of an office building of $4.7 million (see table at end of release).
Net interest expense was $0.5 million compared to $0.7 million in the same period last year. Lower average debt was partially offset by higher average interest rates. The average interest rate on debt was 2.5% compared to 2.0% in the same period last year, primarily due to a higher proportion of fixed rate debt to floating rate debt pursuant to an interest rate swap agreement in place since March 2012.
Equity in losses of partially-owned affiliates was $0.4 million compared to $0.5 million in the same period last year for the Company’s 51% share in Zenara Pharma (“Zenara”), a pharmaceutical company focused on the formulation of finished dosage form products. The Company’s share of Zenara’s losses included $0.2 million and $0.3 million of amortization expense in the first quarters of 2013 and 2012, respectively. Equity in losses of partially-owned affiliates for the first quarters of 2013 and 2012 also included expenses of $0.1 million and income of $0.3 million, respectively, related to an investment in a European joint venture.
The provision for income taxes in the first quarter of 2013 totaled $3.8 million and resulted in an effective tax rate of 24.8%. The effective tax rate in the first quarter of 2013 includes a benefit of $1.3 million due to changes in tax laws and expense of $1.5 million related to the sale of an office building.
Income from continuing operations for the first quarter of 2013 was $11.4 million or $0.37 per share compared to $7.0 million or $0.24 per share in the same period last year.
Capital expenditures and depreciation for the first quarter of 2013 were $12.7 million and $5.3 million, respectively, compared to $2.6 million and $5.4 million in the same period last year, respectively. The increase in capital expenditures in the quarter was primarily driven by a previously announced expansion of the Company’s large-scale manufacturing capacity at one of its sites to support expected growth in the business, including an agreement signed during 2012 to provide commercial launch material for a customer’s clinical phase product.
Financial Expectations – Continuing Operations
The Company continues to expect that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% over 2012, and that full year 2013 adjusted EBITDA will be between $62 and $68 million, an increase of 8% to 18% over 2012. While the Company does not expect to pay cash taxes in the U.S. for the next few years, the Company will record tax expense on U.S. income for the first time in several years beginning in 2013. The Company estimates that its 2013 consolidated effective tax rate will be between 32% and 38%. The tax rate will be sensitive to the geographic mix of income and quarterly effective tax rates may be volatile.
Capital expenditures are expected to be approximately $36 to $40 million and depreciation is expected to be $22 to $24 million in 2013.
These financial expectations are for continuing operations and exclude the impact of any potential M&A, restructuring activities and outcomes of tax disputes, and do not reflect the Company’s stake in Zenara, which is accounted for using the equity method.
The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company’s first quarter 2013 Form 10-Q is filed with the SEC.
Conference Call and Webcast
A conference call to discuss the Company’s first quarter 2013 results will begin at 8:30 a.m. Eastern Time on Friday, May 3, 2013 and last approximately 45 minutes. Those wishing to participate should call 1-888-572-7025 for domestic and +719-325-2484 for international. Please use the pass code 3383897 and call approximately 10 minutes prior to start time. A webcast will be available on the Investors section on the Cambrex website located at www.cambrex.com. A telephone replay of the conference call will be available through Friday, May 10, 2013 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international. Please use the pass code 3383897 to access the replay.
Forward Looking Statements
This document contains “forward-looking statements,” including statements regarding expected performance, especially those set forth under the heading “Financial Expectations – Continuing Operations,” including the Company’s expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% versus 2012, that full year 2013 adjusted EBITDA will be between $62 and $68 million, that capital expenditures will be approximately $36 to $40 million and that depreciation will be $22 to $24 million in 2013. These and other forward looking statements may be identified by the fact that they use words such as “expects,” “anticipates,” “intends,” “estimates,” “believes” or similar expressions. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. The factors described in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the period ended December 31, 2012, captioned “Risk Factors,” or otherwise described in the Company’s filings with the SEC, as well as any cautionary language in the Company’s Annual Report on Form 10-K for the period ended December 31, 2012, provide examples of such risks and uncertainties that may cause the Company’s actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, governmental legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company’s public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company’s ability to receive regulatory approvals for its products, as well as risks relating to a Phase 3 supply agreement signed during 2012 including that the Company will expend significant resources to expand its manufacturing facilities without any assurance that the new agreement will generate any revenue beyond revenue that would be earned under termination provisions within the agreement, that the customer’s product candidate will be successful in Phase 3 trials or obtain the necessary regulatory approvals to commercialize the product candidate, that the customer’s Phase 3 program will not be terminated early, that anticipated quantities will not be meaningfully reduced, that the planned Phase 3 and pre-launch activities will proceed on the timeline anticipated, if at all, that the Company’s expansion will proceed on the anticipated timeline without disruption to existing customers or its new customer and without disruption to the Company’s and its customers’ ability to meet key product delivery milestones.
For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including the Forward-Looking Statement sections therein, and other filings with the SEC. The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.
Use of Non-GAAP Financial Measures
EBITDA is a non-GAAP financial measure, which the Company defines as operating profit plus depreciation and amortization expense. Other companies may have a different definition of EBITDA and, therefore, EBITDA may not be comparable with non-GAAP financial measures provided by other companies. EBITDA should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex’s liquidity. Cambrex uses EBITDA as one of several metrics to assess and analyze its operational results and trends. Cambrex also believes it is useful to investors because it is a common operating performance metric as well as a metric routinely used to assess potential enterprise value. Cambrex has provided a reconciliation from U.S. GAAP amounts to non-GAAP amounts at the end of this press release.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (“APIs”), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.
CAMBREX CORPORATION Statements of Profit and Loss For the Quarters Ended March 31, 2013 and 2012 (in thousands, except per-share data) 2013 2012 ---- ---- % of % of Amount Sales Amount Sales ------ ----- ------ ----- Gross Sales $74,581 $70,559 Commissions, Allowances and Rebates 163 535 --- --- Net Sales 74,418 70,024 Other 467 204 --- --- Net Revenues 74,885 70,228 Cost of Goods Sold 50,136 67.2% 47,800 67.7% ------ ------ Gross Profit 24,749 33.2% 22,428 31.8% Operating Expenses Selling, General and Administrative Expenses 11,104 14.9% 9,960 14.1% Research and Development Expenses 2,194 2.9% 2,358 3.3% Total Operating Expenses 13,298 17.8% 12,318 17.5% ------ ------ Gain on Sale of Asset 4,680 6.3% - - Operating Profit 16,131 21.6% 10,110 14.3% Other Expenses/(Income): Interest Expense, net 495 651 Other (Income)/Expenses, net (32) 8 Equity in Losses of Partially-Owned Affiliates 481 208 --- --- Income Before Income Taxes 15,187 20.4% 9,243 13.1% Provision for Income Taxes 3,762 2,205 ----- ----- Income from Continuing Operations $11,425 15.3% $7,038 10.0% Loss from Discontinued Operations, Net of Tax (257) - ---- --- Net Income $11,168 15.0% $7,038 10.0% Basic Earnings/(Loss) per Share of Common Stock: Income from Continuing Operations $0.38 $0.24 Loss from Discontinued Operations, Net of Tax $(0.01) $ - --- Net Income $0.37 $0.24 Diluted Earnings/(Loss) per Share of Common Stock: Income from Continuing Operations $0.37 $0.24 Loss from Discontinued Operations, Net of Tax $(0.01) $ - --- Net Income $0.36 $0.24 Weighted Average Shares Outstanding Basic 29,970 29,602 Diluted 30,788 29,886
CAMBREX CORPORATION Consolidated Balance Sheets As of March 31, 2013 and December 31, 2012 (in thousands) March 31, December 31, Assets 2013 2012 ------ ---- ---- Cash and Cash Equivalents $31,877 $23,551 Trade Receivables, net 41,070 43,094 Inventories, net 74,066 71,221 Prepaid Expenses and Other Current Assets 8,727 6,104 ----- ----- Total Current Assets 155,740 143,970 Property, Plant and Equipment, net 155,735 151,815 Goodwill 36,426 37,312 Intangible Assets, net 3,910 4,091 Investments in and Advances to Partially-Owned Affiliates 15,241 15,094 Deferred Income Taxes 37,588 39,262 Other Non-Current Assets 5,878 2,924 ----- ----- Total Assets $410,518 $394,468 Liabilities and Stockholders' Equity ----------------------------- Accounts Payable $25,725 $27,612 Deferred Revenue 12,055 11,570 Accrued Expenses and Other Current Liabilities 39,414 43,844 ------ ------ Total Current Liabilities 77,194 83,026 Long-Term Debt 73,000 64,000 Deferred Income Taxes 19,838 18,577 Accrued Pension Benefits 54,630 55,373 Other Non-Current Liabilities 14,129 10,195 ------ ------ Total Liabilities $238,791 $231,171 Stockholders' Equity $171,727 $163,297 Total Liabilities and Stockholders' Equity $410,518 $394,468
CAMBREX CORPORATION Reconciliation of GAAP to non-GAAP Results For the Quarters Ended March 31, 2013 and 2012 (in thousands) First First Quarter Quarter 2013 2012 -------- -------- Operating Profit $16,131 $10,110 Gain on Sale of Asset (4,680) - ------ --- Adjusted Operating Profit 11,451 10,110 Depreciation and Amortization 5,333 5,486 ----- ----- Adjusted EBITDA $16,784 $15,596
SOURCE Cambrex Corporation